Teva Pharmaceuticals (Netherlands)

Recent papers from Teva Pharmaceuticals (Netherlands)

1. Patient Experience With Once-daily Deutetrabenazine Extended-release Tablets for the Treatment of Tardive Dyskinesia in Individuals With Prior Valbenazine Use (P7-16.003)Neurology · 2026
2. Evaluating the Complementary Nature of Randomized Controlled Trials and Real-World Evidence Using Over 5 Years of Experience with Fremanezumab: A Narrative ReviewAdvances in Therapy · 2026
3. Impact of Early Fremanezumab Initiation and Treatment Pauses on the Reduction of Monthly Migraine Days: Analyses from the PEARL Study (P10-15.007)Neurology · 2026
4. Blocking Host Factors IAP and DDX3 Activates HIV-1 Transcription and Increases Apoptosis Sensitivity of HIV-1 Infected CellsPathogens · 2026
5. Real-world patient characteristics, treatment patterns, and healthcare resource utilization and costs of tardive dyskinesia in GermanyJournal of Psychiatric Research · 2026
6. Real-World Clinical Effectiveness and Migraine-Related Healthcare Resource Utilization in Patients Initiating Fremanezumab in Germany and the United KingdomTherapeutics and Clinical Risk Management · 2026
7. Addressing unmet needs in migraine: Real-world fremanezumab effectiveness in participants of the PEARL study with at least three prior preventive treatment failuresCephalalgia · 2025
8. The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectivenessNeurological Sciences · 2025
9. Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL studyNeurological Sciences · 2025
10. US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart ReviewAdvances in Therapy · 2025
11. Ultrasound Localization Microscopy Imaging by Monodisperse Microbubble Uncoupling: First Experimental Study2024
12. Uncovering patterns of inhaler technique and reliever use: the value of objective, personalized data from a digital inhalernpj Primary Care Respiratory Medicine · 2024
13. A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapyBMC Neurology · 2024
14. Efficacy and Safety of Fremanezumab in Patients with Migraine and Obesity: Post Hoc Analysis of the Phase 3 HALO-LTS and FOCUS Clinical Trials (P8-12.001)Neurology · 2024
15. A Prospective, Observational Study to Evaluate the Long-term Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice (P8-12.007)Neurology · 2024
16. Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive ResponsePain and Therapy · 2024
17. The first interim analysis of Italian patients enrolled in the real-world, Pan-European, prospective, observational, phase 4 PEARL study of fremanezumab effectivenessNeurological Sciences · 2024
18. In vitro comparison of subharmonic-aided pressure estimation sensitivity among microfluidic monodisperse microbubbles, sonazoid, and definityThe Journal of the Acoustical Society of America · 2024
19. Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxelCancer Drug Resistance · 2024
20. Cost-Effectiveness and Impact on Health Care Utilization of Interventions to Improve Medication Adherence and Outcomes in Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature ReviewThe Journal of Allergy and Clinical Immunology In Practice · 2024